Point72 Asset Management L.P. grew its position in Kadmon Holdings, Inc. (NASDAQ:KDMN) by 50.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 11,785,115 shares of the company’s stock after purchasing an additional 3,927,415 shares during the period. Point72 Asset Management L.P. owned about 0.07% of Kadmon worth $45,844,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in KDMN. Signature Wealth Management Partners LLC acquired a new stake in shares of Kadmon during the first quarter worth approximately $39,000. Brinker Capital Investments LLC acquired a new stake in shares of Kadmon during the first quarter worth approximately $40,000. Aigen Investment Management LP acquired a new stake in shares of Kadmon during the first quarter worth approximately $42,000. Teacher Retirement System of Texas acquired a new stake in shares of Kadmon during the fourth quarter worth approximately $47,000. Finally, Ground Swell Capital LLC acquired a new stake in shares of Kadmon during the first quarter worth approximately $51,000. Institutional investors own 96.86% of the company’s stock.
Several analysts recently commented on KDMN shares. UBS Group started coverage on shares of Kadmon in a report on Thursday, May 20th. They set a “buy” rating and a $9.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Kadmon in a research note on Friday, March 26th. Jefferies Financial Group lifted their target price on shares of Kadmon from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday. Oppenheimer lifted their target price on shares of Kadmon from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Zacks Investment Research upgraded shares of Kadmon from a “sell” rating to a “hold” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $11.83.
Kadmon (NASDAQ:KDMN) last released its quarterly earnings results on Thursday, May 6th. The company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.01. Kadmon had a negative net margin of 5,103.69% and a negative return on equity of 142.70%. The company had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.72 million. As a group, research analysts expect that Kadmon Holdings, Inc. will post -0.72 EPS for the current fiscal year.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer.
Want to see what other hedge funds are holding KDMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kadmon Holdings, Inc. (NASDAQ:KDMN).
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.